BRIEF—Hikma debuts generic Onfi in USA

London-headquartered Hikma Pharmaceuticals’ US subsidiary has launched clobazam oral suspension, 2.5mg/mL, and clobazam tablets, 10mg and 20mg, the generic equivalent to Onfi, which is marketed by Danish CNS specialist Lundbeck.

Hikma’s clobazam is a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years of age or older.

According to IQVIA, US sales of clobazam oral suspension were around $260 million and of clobazam tablets were about $601 million in the 12 months ending September 2018.

Brian Hoffmann, president of the Generics Division at Hikma, said: “We are very excited to add clobazam oral suspension and clobazam tablets to our product portfolio. This will be among the first generics available on the market and we are pleased to improve patients’ access to this important medicine.”